-
Publication Venue For
-
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology..
21:67-81.
2023
-
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023..
20:1288-1298.
2022
-
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study..
20:1255-1266.e11.
2022
-
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022..
20:1204-1214.
2022
-
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology..
20:1267-1275.
2022
-
Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis..
20:1099-1106.e2.
2022
-
Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia..
20:1116-1123.
2022
-
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..
20:925-951.
2022
-
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022..
20:754-764.
2022
-
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..
20:815-833.
2022
-
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology..
20:691-722.
2022
-
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022..
20:622-634.
2022
-
Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016..
20:379-386.e9.
2022
-
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..
20:285-308.
2022
-
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..
20:167-192.
2022
-
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022..
19:1382-1394.
2021
-
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..
19:1277-1303.
2021
-
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021..
19:1218-1230.
2021
-
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..
19:1181-1201.
2021
-
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021..
19:1006-1019.
2021
-
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021..
19:888-895.
2021
-
NCCN Guidelines® Insights: Palliative Care, Version 2.2021..
19:780-788.
2021
-
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..
19:839-868.
2021
-
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..
19:541-565.
2021
-
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021..
19:364-376.
2021
-
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..
19:329-359.
2021
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021..
19:254-266.
2021
-
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..
19:191-226.
2021
-
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..
19:77-102.
2021
-
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021..
19:16-27.
2021
-
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology..
18:1685-1717.
2020
-
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021..
18:1604-1612.
2020
-
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology..
18:1537-1570.
2020
-
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021..
18:1460-1467.
2020
-
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology..
18:1248-1269.
2020
-
Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma..
18:1087-1095.
2020
-
Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions..
18:825-831.
2020
-
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..
18:873-898.
2020
-
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020..
18:806-815.
2020
-
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..
18:755-781.
2020
-
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020..
18:660-666.
2020
-
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy..
18:676-681.
2020
-
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..
18:599-634.
2020
-
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020..
18:522-536.
2020
-
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020..
18:380-391.
2020
-
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology..
18:329-354.
2020
-
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020..
18:230-241.
2020
-
Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts..
18:250-259.
2020
-
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology..
18:185-217.
2020
-
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019..
18:120-131.
2020
-
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..
18:81-112.
2020
-
Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis..
18:52-58.
2020
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020..
17:1464-1472.
2019
-
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..
17:1529-1554.
2019
-
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..
17:1374-1391.
2019
-
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020..
17:1278-1285.
2019
-
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020..
17:1154-1165.
2019
-
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology..
17:1109-1133.
2019
-
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology..
17:977-1007.
2019
-
Authors' Reply..
17:xxxixa-xl.
2019
-
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019..
17:896-909.
2019
-
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..
17:855-883.
2019
-
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology..
17:721-749.
2019
-
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019..
17:650-661.
2019
-
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..
17:479-505.
2019
-
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..
17:367-402.
2019
-
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019..
17:302-310.
2019
-
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011..
17:245-254.
2019
-
Management of Immunotherapy-Related Toxicities, Version 1.2019..
17:255-289.
2019
-
Pancreatic Adenocarcinoma, Version 1.2019..
17:202-210.
2019
-
Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry..
17:127-139.
2019
-
NCCN Guidelines Insights: Breast Cancer, Version 3.2018..
17:118-126.
2019
-
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology..
17:64-84.
2019
-
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019..
17:12-20.
2019
-
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018..
16:1429-1440.
2018
-
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..
16:1500-1537.
2018
-
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018..
16:1289-1303.
2018
-
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology..
16:1108-1135.
2018
-
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018..
16:1041-1053.
2018
-
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..
16:852-871.
2018
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018..
16:807-821.
2018
-
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..
16:874-901.
2018
-
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology..
16:742-774.
2018
-
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018..
16:693-702.
2018
-
Management of Locoregional Rectal Cancer..
16:617-619.
2018
-
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018..
16:479-490.
2018
-
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..
16:536-563.
2018
-
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology..
16:412-441.
2018
-
NCCN Guidelines Insights: Colon Cancer, Version 2.2018..
16:359-369.
2018
-
NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening..
16:444-449.
2018
-
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology..
16:310-320.
2018
-
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018..
16:245-254.
2018
-
Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study..
16:267-273.
2018
-
Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer..
16:201-209.
2018
-
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018..
16:123-135.
2018
-
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology..
16:170-199.
2018
-
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..
16:66-97.
2018
-
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018..
16:11-20.
2018
-
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..
15:1520-1541.
2017
-
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..
15:1414-1427.
2017
-
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017..
15:1331-1345.
2017
-
NCCN Guidelines Insights: Palliative Care, Version 2.2017..
15:989-997.
2017
-
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..
15:1028-1061.
2017
-
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology..
15:926-957.
2017
-
Developments in Molecular Testing and Biosimilars..
15:772-782.
2017
-
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..
15:804-834.
2017
-
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017..
15:761-770.
2017
-
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology..
15:608-638.
2017
-
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017..
15:563-573.
2017
-
Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'..
15:lxx-lxxii.
2017
-
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017..
15:293-311.
2017
-
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology..
15:230-269.
2017
-
NCCN Guidelines Insights: Bone Cancer, Version 2.2017..
15:155-167.
2017
-
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..
15:60-87.
2017
-
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017..
14:1505-1512.
2016
-
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016..
14:1357-1370.
2016
-
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..
14:1430-1468.
2016
-
Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening..
14:1479-1485.
2016
-
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology..
14:1286-1312.
2016
-
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016..
14:1213-1224.
2016
-
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016..
14:1067-1079.
2016
-
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..
14:1134-1163.
2016
-
Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures..
14:993-998.
2016
-
NCCN Guidelines Insights: Melanoma, Version 3.2016..
14:945-958.
2016
-
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016..
14:825-836.
2016
-
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology..
14:758-786.
2016
-
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..
14:574-597.
2016
-
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016..
14:509-519.
2016
-
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology..
14:450-473.
2016
-
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016..
14:389-400.
2016
-
A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments..
14:311-319.
2016
-
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..
14:324-354.
2016
-
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016..
14:255-264.
2016
-
Diffuse Large B-Cell Lymphoma Version 1.2016..
14:196-231.
2016
-
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015..
14:153-162.
2016
-
Palliative Care Version 1.2016..
14:82-113.
2016
-
Prostate Cancer, Version 1.2016..
14:19-30.
2016
-
NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015..
13:1534-1561.
2015
-
NCCN Guidelines Insights Breast Cancer, Version 1.2016..
13:1475-1485.
2015
-
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology..
13:1398-1435.
2015
-
Anemia and Functional Disability in Older Adults With Cancer..
13:1233-1239.
2015
-
Central Nervous System Cancers, Version 1.2015..
13:1191-1202.
2015
-
Anaplastic Thyroid Carcinoma, Version 2.2015..
13:1140-1150.
2015
-
It May Be Time to Abandon Urine Tests for Bladder Cancer..
13:1163-1166.
2015
-
CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers..
13:1005-1011.
2015
-
Growth and Change at NCCN..
13:946.
2015
-
Head and Neck Cancers, Version 1.2015..
13:847-855.
2015
-
Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?.
13:755-761.
2015
-
Rectal Cancer, Version 2.2015..
13:719-728.
2015
-
Hodgkin lymphoma, version 2.2015..
13:554-586.
2015
-
New treatment options in castration-resistant prostate cancer..
13:690-693.
2015
-
Breast Cancer Version 2.2015..
13:448-475.
2015
-
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms..
13:424-434.
2015
-
Routine use of zoledronic acid in early-stage breast cancer..
13:480-486.
2015
-
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015..
13:326-362.
2015
-
Myelodysplastic syndromes, version 2.2015..
13:261-272.
2015
-
Esophageal and esophagogastric junction cancers, version 1.2015..
13:194-227.
2015
-
VATS versus open surgery for lung cancer resection: moving toward a minimally invasive approach..
13:162-164.
2015
-
Management of chemotherapy-induced neutropenia: measuring quality, cost, and value..
13:e1-e7.
2015
-
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines..
12:1517-1523.
2014
-
Chronic myelogenous leukemia, version 1.2015..
12:1590-1610.
2014
-
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology..
12:1454-1487.
2014
-
Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines..
12:1379-1388.
2014
-
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014..
12:1326-1338.
2014
-
Non-Hodgkin's lymphomas, version 4.2014..
12:1282-1303.
2014
-
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines..
12:1211-1219.
2014
-
Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines..
12:1083-1093.
2014
-
Building the palliative care evidence base: Lessons from a randomized controlled trial of oxygen vs room air for refractory dyspnea..
12:989-992.
2014
-
Colon cancer, version 3.2014..
12:1028-1059.
2014
-
Occult primary, version 3.2014..
12:969-974.
2014
-
Gastrointestinal stromal tumors, version 2.2014..
12:853-862.
2014
-
Non-Hodgkin's lymphomas, version 2.2014..
12:916-946.
2014
-
Melanoma, version 4.2014..
12:621-629.
2014
-
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes..
12:719-726.
2014
-
Prostate cancer, version 2.2014..
12:686-718.
2014
-
Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?.
12:821-824.
2014
-
Breast cancer version 3.2014..
12:542-590.
2014
-
Soft tissue sarcoma, version 2.2014..
12:473-483.
2014
-
Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute..
12 Suppl 1:S21-S24.
2014
-
Adolescent and young adult oncology, version 2.2014..
12:21-32.
2014
-
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology ..
12:82-126.
2014
-
Prostate cancer, version 1.2014..
11:1471-1479.
2013
-
Chronic Myelogenous Leukemia, Version 1.2014..
11:1327-1340.
2013
-
Venous thromboembolic disease..
11:1402-1429.
2013
-
Moving forward with myeloid growth factors..
11:1181-1182.
2013
-
Myeloid growth factors..
11:1266-1290.
2013
-
Ovarian cancer, version 2.2013..
11:1199-1209.
2013
-
Will biosimilars gain momentum?.
11:1291-1297.
2013
-
Acute myeloid leukemia, version 2.2013..
11:1047-1055.
2013
-
Central nervous system cancers..
11:1114-1151.
2013
-
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines..
11:917-923.
2013
-
An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse..
11:745-749.
2013
-
Breast cancer, version 3.2013: featured updates to the NCCN guidelines..
11:753-760.
2013
-
Myelodysplastic syndromes: clinical practice guidelines in oncology..
11:838-874.
2013
-
Bone cancer..
11:688-723.
2013
-
Non-small cell lung cancer, version 2.2013..
11:645-653.
2013
-
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines..
11:531-546.
2013
-
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines..
11:519-528.
2013
-
Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches..
11:548-557.
2013
-
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology..
11:562-576.
2013
-
Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis..
11:477-484.
2013
-
Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration..
11:431-441.
2013
-
Non-Hodgkin's lymphomas, version 1.2013..
11:257-272.
2013
-
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines..
11:141-152.
2013
-
Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers..
11:60-66.
2013
-
Multiple myeloma, version 1.2013..
11:11-17.
2013
-
Small cell lung cancer..
11:78-98.
2013
-
Non-Hodgkin's Lymphomas, version 3.2012..
10:1487-1498.
2012
-
Rectal cancer..
10:1528-1564.
2012
-
Ovarian cancer, version 3.2012..
10:1339-1349.
2012
-
Non-small cell lung cancer..
10:1236-1271.
2012
-
Palliative care..
10:1284-1309.
2012
-
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013..
10:1211-1219.
2012
-
Adolescent and young adult oncology. Clinical practice guidelines in oncology..
10:1112-1150.
2012
-
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines..
10:1081-1087.
2012
-
NCCN Clinical Practice Guidelines Acute myeloid leukemia..
10:984-1021.
2012
-
Optimal management of malignant pleural effusions (results of CALGB 30102)..
10:975-982.
2012
-
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines..
10:951-960.
2012
-
First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions..
10:847-856.
2012
-
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines..
10:821-829.
2012
-
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines..
10:703-713.
2012
-
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme..
10:695-699.
2012
-
Cancer- and chemotherapy-induced anemia..
10:628-653.
2012
-
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines..
10:589-597.
2012
-
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement..
10:599-613.
2012
-
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines..
10:449-454.
2012
-
Mucosal melanoma of the head and neck..
10:320-338.
2012
-
Senior adult oncology..
10:162-209.
2012
-
Chronic myelogenous leukemia..
10:64-110.
2012
-
Malignant pleural mesothelioma..
10:26-41.
2012
-
NCCN Clinical Practice Guidelines Occult primary..
9:1358-1395.
2011
-
Colon cancer..
9:1238-1290.
2011
-
Multiple myeloma..
9:1146-1183.
2011
-
Small cell lung cancer..
9:1086-1113.
2011
-
Hodgkin lymphoma..
9:1020-1058.
2011
-
Kidney cancer..
9:960-977.
2011
-
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives..
9 Suppl 4:S1-22.
2011
-
Biosimilars: are they ready for primetime in the United States?.
9:934-942.
2011
-
Esophageal and esophagogastric junction cancers..
9:830-887.
2011
-
Long-term outcomes of myeloid growth factor treatment..
9:945-952.
2011
-
Myeloid growth factors..
9:914-932.
2011
-
Heparin-induced thrombocytopenia in cancer..
9:781-787.
2011
-
Venous thromboembolic disease..
9:714-777.
2011
-
Controversies in the locoregional management of head and neck cancer..
9:653-662.
2011
-
Head and neck cancers..
9:596-650.
2011
-
Non-Hodgkin's lymphomas..
9:484-560.
2011
-
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma..
9:414-427.
2011
-
Central nervous system cancers..
9:352-400.
2011
-
Acute myeloid leukemia..
9:280-317.
2011
-
Invasive breast cancer..
9:136-222.
2011
-
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia..
9 Suppl 2:S1-25.
2011
-
Epithelial ovarian cancer..
9:82-113.
2011
-
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes..
9:30-56.
2011
-
Controversies in Breast Cancer Screening Strategies.
2016